Skip to main content

Table 3 hATTR-PN patients clinical characteristics

From: Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study

Characteristics

Patients

No. Subjects (no. visits)

733 (2913)

Age at onset, years

 Mean ± SD

38.1 ± 12.6

 Median (IQR)

34 (29–44)

Late-onset, n (%)

116 (15.8)

Disease duration at THAOS enrolment, years

 Mean ± SD

4.5 ± 4.8

Age at diagnosis, years

 Mean ± SD

39.4 ± 12.9

 Median (IQR)

35 (30–45)

Disease mPND stage, n (%)

 stage I

537 (73.3)

 stage II

141 (19.2)

 stage IIIa

22 (3)

 stage IIIb

12 (1.6)

 stage IV

21 (2.9)

Disease Coutinho stage, n (%)

 stage 1

678 (92.5)

 stage 2

34 (4.6)

 stage 3

21 (2.9)

Visit, n

 1

733

 2

641

 3

526

 4

419

 5

298

 6

187

 7

88

 8

16

 9

5

Treated, n (%)

637 (86.9)

  1. Clinical characteristics measured at THAOS enrolment or first EQ-5D-3L response; Treatment variable status measured across follow-up; SD denotes standard deviation, IQR interquartile range